[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

US3970656A - 1-Alkyl-4-m-hydroxyphenyl-4-propionyl piperidines - Google Patents

1-Alkyl-4-m-hydroxyphenyl-4-propionyl piperidines Download PDF

Info

Publication number
US3970656A
US3970656A US05/478,547 US47854774A US3970656A US 3970656 A US3970656 A US 3970656A US 47854774 A US47854774 A US 47854774A US 3970656 A US3970656 A US 3970656A
Authority
US
United States
Prior art keywords
hydroxyphenyl
propionylpiperidine
alkyl
hydrobromide
amyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US05/478,547
Inventor
Everette Lee May
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Government
Original Assignee
US Government
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Government filed Critical US Government
Priority to US05/478,547 priority Critical patent/US3970656A/en
Application granted granted Critical
Publication of US3970656A publication Critical patent/US3970656A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms

Definitions

  • the invention relates to phenylpiperidines of the formula ##SPC2##
  • R is alkyl of 4 to 7 carbon atoms or pharmaceutically acceptable acid addition salts thereof.
  • the compounds of formula I are useful as non-addicting analgesics.
  • alkyl of 4 to 7 carbon atoms is understood to mean straight or branched chain alkyl of 4 to 7 carbon atoms, such as, butyl, isobutyl, amyl, isoamyl, hexyl, heptyl or the like.
  • R is straight or branched chain alkyl of 4 to 7 carbon atoms.
  • the compounds of formula I form acid addition salts and such salts are also within the scope of this invention.
  • the compounds of formula I form pharmaceutically acceptable acid addition salts with, for example, both pharmaceutically acceptable organic and inorganic acids, such as, acetic acid, succinic acid, formic acid, methanesulfonic acid, p-toluenesulfonic acid, nitric acid, phosphoric acid, sulfuric acid, hydrochloric acid, hydrobromic acid and the like.
  • a preferred compound of the invention is 1-amyl-4-m-hydroxyphenyl-4-propionylpiperidine.
  • the compounds of formula I are prepared by treating 4-m-methoxyphenyl-4-propionylpiperidine or its salts, for example, the hydrochloride, with an alkyl iodide or bromide, wherein the alkyl group is a straight or branched chain alkyl of 4 to 7 carbon atoms, in an inert organic solvent, such as 2-butanone, dimethylformamide or the like.
  • the reaction is carried out at a temperature in the range of from about 80° to about 120°; preferably, the reflux temperature of the reaction mixture.
  • the 4-m-methoxyphenyl-4-propionylpiperidine starting material can be prepared from 4-m-methoxyphenyl-1-methyl-4-propionylpiperidine as hereinafter described in Example 2.
  • the 4-m-methoxyphenyl-1-methyl-4-propionylpiperidine precursor can be prepared according to known procedures, see for instance, Example 1 and A. W. D. Avison and A. L. Morrison, J. Chem. Soc., 1470 (1950).
  • the compounds of formula I as well as their pharmaceutically acceptable acid addition salts, are useful as non-addicting analgesic agents.
  • the useful analgesic activity of the compounds of formula I can be demonstrated in warm blooded animals utilizing standard procedures. Exemplary of such procedures are (1) Hot-plate test -- T. D. Perrine, L. Atwell, I. B. Tice, A. E. Jacobson and E. L. May, J. Pharm. Sci., 61, 86 (1972), (2) Nilsen test -- T. D. Perrine et al., supra, and (3) Physical Dependence Capacity Test in rhesus monkeys -- J. E. Villareal, "Advances in Mental Science", Vol. II, R. T. Harris, W. McIsaac and C. R. Schuster, Ed., University of Texas Press, Houston, Texas, 1970, pp. 83-116. When compounds of the invention are utilized as the test substances in the foregoing tests the results set forth in Table I are obtained.
  • the products of the invention can be incorporated into standard pharmaceutical dosage forms, for example, they are useful for oral or parenteral application with the usual pharmaceutical adjuvant material, e.g., organic or inorganic inert carrier materials such as water, gelatin, lactose, starch, magnesium stearate, talc, vegetable oils, gums, polyalkylene-glycols, Vaseline, etc.
  • the pharmaceutical preparations can be employed in a solid form, e.g., as tablets, troches, suppositories, capsules, or in liquid form, e.g., as solutions, suspensions or emulsions.
  • the pharmaceutical adjuvant material can include preservatives, stabilizers, wetting or emulsifying agents, salts to change the osmotic pressure or to act as buffers. They can also contain other therapeutically active materials.
  • 1-Amyl-4-m-hydroxyphenyl-4-propionyl-piperidine hydrobromide, lactose, corn starch and Amijel BOll are blended in a suitable mixer.
  • the mixture is granulated to a heavy paste with water and the moist mass is passed through a No. 12 screen. It is then dried overnight at 100°F.
  • the dried granules are passed through a No. 16 screen and transferred to a suitable mixer.
  • the calcium stearate is added and mixed until uniform.
  • the mixture is compressed at a tablet weight of 410 mg. using tablet punches having a diameter of approximately 3/8 inch. (Tablets may be either flat or biconvex and may be scored if desired.)
  • 1-Amyl-4-m-hydroxyphenyl-4-propionyl-piperidine hydrobromide and corn starch are mixed together and passed though a No. 00 screen in Model "J" Fitzmill with hammers forward. This premix is then mixed with dicalcium phosphate and one-half of the magnesium stearate, passed though a No. 1A screen in Model "J". The slugs are passed through a No. 2A plate in a Model "D" Fitzmill at slow speed with knives forward, and the remaining magnesium stearate is added. The mixture is mixed and compressed.
  • 1-Amyl-4-m-hydroxyphenyl-4-propionyl-piperidine hydrobromide is mixed with lactose and corn starch in a suitable mixer.
  • the mixture is further blended by passing through a Fitzpatric Comminuting Machine with a No. 1A screen with knives forward.
  • the blended powder is returned to the mixer, the talc added and blended thoroughly.
  • the mixture is filled into No. 4 hard shell gelatin capsules on a Parke Davis capsulating machine.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Phenylpiperidines of the formula ##SPC1##
Wherein R is alkyl of 4 to 7 carbon atoms are described. The foregoing phenylpiperidines are useful as non-addicting analgesics.

Description

BRIEF SUMMARY OF THE INVENTION
The invention relates to phenylpiperidines of the formula ##SPC2##
Wherein R is alkyl of 4 to 7 carbon atoms or pharmaceutically acceptable acid addition salts thereof. The compounds of formula I are useful as non-addicting analgesics.
DETAILED DESCRIPTION OF THE INVENTION
As used herein, the term "alkyl of 4 to 7 carbon atoms" is understood to mean straight or branched chain alkyl of 4 to 7 carbon atoms, such as, butyl, isobutyl, amyl, isoamyl, hexyl, heptyl or the like.
The compounds of the invention are characterized by the formula ##SPC3##
Wherein R is straight or branched chain alkyl of 4 to 7 carbon atoms. The compounds of formula I form acid addition salts and such salts are also within the scope of this invention. Thus, the compounds of formula I form pharmaceutically acceptable acid addition salts with, for example, both pharmaceutically acceptable organic and inorganic acids, such as, acetic acid, succinic acid, formic acid, methanesulfonic acid, p-toluenesulfonic acid, nitric acid, phosphoric acid, sulfuric acid, hydrochloric acid, hydrobromic acid and the like.
Exemplary of the compounds of formula I are:
1-butyl-4-m-hydroxyphenyl-4-propionylpiperidine;
1-amyl-4-m-hydroxyphenyl-4-propionylpiperidine;
1-hexyl-4-m-hydroxyphenyl-4-propionylpiperidine;
1-heptyl-4-m-hydroxyphenyl-4-propionylpiperidine; and the like.
A preferred compound of the invention is 1-amyl-4-m-hydroxyphenyl-4-propionylpiperidine.
The compounds of formula I are prepared by treating 4-m-methoxyphenyl-4-propionylpiperidine or its salts, for example, the hydrochloride, with an alkyl iodide or bromide, wherein the alkyl group is a straight or branched chain alkyl of 4 to 7 carbon atoms, in an inert organic solvent, such as 2-butanone, dimethylformamide or the like. The reaction is carried out at a temperature in the range of from about 80° to about 120°; preferably, the reflux temperature of the reaction mixture.
The resultant N-alkyl methyl ether is then treated with 48% HBr at reflux to obtain the corresponding phenylpiperidine of formula I.
The 4-m-methoxyphenyl-4-propionylpiperidine starting material can be prepared from 4-m-methoxyphenyl-1-methyl-4-propionylpiperidine as hereinafter described in Example 2.
The 4-m-methoxyphenyl-1-methyl-4-propionylpiperidine precursor can be prepared according to known procedures, see for instance, Example 1 and A. W. D. Avison and A. L. Morrison, J. Chem. Soc., 1470 (1950).
The compounds of formula I, as well as their pharmaceutically acceptable acid addition salts, are useful as non-addicting analgesic agents.
The useful analgesic activity of the compounds of formula I can be demonstrated in warm blooded animals utilizing standard procedures. Exemplary of such procedures are (1) Hot-plate test -- T. D. Perrine, L. Atwell, I. B. Tice, A. E. Jacobson and E. L. May, J. Pharm. Sci., 61, 86 (1972), (2) Nilsen test -- T. D. Perrine et al., supra, and (3) Physical Dependence Capacity Test in rhesus monkeys -- J. E. Villareal, "Advances in Mental Science", Vol. II, R. T. Harris, W. McIsaac and C. R. Schuster, Ed., University of Texas Press, Houston, Texas, 1970, pp. 83-116. When compounds of the invention are utilized as the test substances in the foregoing tests the results set forth in Table I are obtained.
                                  TABLE I                                 
__________________________________________________________________________
                               Antagonist                                 
Compound.sup.(a)                                                          
                Hot-plate                                                 
                      Nilsen                                              
                          PDC.sup.(b)                                     
                               Activity                                   
__________________________________________________________________________
1-butyl-4-m-hydroxyphenyl                                                 
                1.7        Low No                                         
 4-propionylpiperidine                                                    
1-amyl-4-m-hydroxyphenyl-                                                 
                0.3   0.4 No   Yes                                        
 4-propionylpiperidine                                                    
1-hexyl-4-m-hydroxyphenyl-                                                
                3.0   2.4 No   Yes                                        
 4-propionylpiperidine                                                    
1-heptyl-4-m-hydroxyphenyl-                                               
                3.7   3.5 No   Yes                                        
 4-propionylpiperidine                                                    
__________________________________________________________________________
 .sup.(a) administered as the hydrobromide salt                           
 .sup.(b) physical dependence capacity
The products of the invention can be incorporated into standard pharmaceutical dosage forms, for example, they are useful for oral or parenteral application with the usual pharmaceutical adjuvant material, e.g., organic or inorganic inert carrier materials such as water, gelatin, lactose, starch, magnesium stearate, talc, vegetable oils, gums, polyalkylene-glycols, Vaseline, etc. The pharmaceutical preparations can be employed in a solid form, e.g., as tablets, troches, suppositories, capsules, or in liquid form, e.g., as solutions, suspensions or emulsions. The pharmaceutical adjuvant material can include preservatives, stabilizers, wetting or emulsifying agents, salts to change the osmotic pressure or to act as buffers. They can also contain other therapeutically active materials.
The following examples further illustrate the invention. All temperatures are in degrees Centigrade, unless otherwise mentioned.
EXAMPLE 1 Preparation of 1-m-methoxyphenyl-1-propionoxypiperidine
To the Grignard reagent prepared (in diethylether) from 23.4 g. of Magnesium and 150 g. of ethyl iodide was added (efficient stirring) 55 g. of 4-cyano-4-m-methoxyphenyl-1-methylpiperidine in 400 ml. of benzene. The diethylether was distilled and the mixture was refluxed for 1 hour. After cooling, 80 g. of ammonium chloride in water was added. The separated organic layer was washed with dilute potassium hydroxide and refluxed for 30 minutes with 600 ml. of 2N HCl. The aqueous layer was separated, washed with benzene, made alkaline with potassium hydroxide pellets, and extracted with benzene. The extract was dried with Na2 SO4 and evaporated to give an oil (46 g.); b.p. 160°-161° (2mm); yield 40.5 g. (65%); ν1710 cm- 1.
EXAMPLE 2 Preparation of 4-m-methoxyphenyl-1-propionylpiperidine hydrochloride
To a stirred solution of 25 g. of ethyl chloroformate in 80 ml. of benzene was added 20.5 g. of 1-m-methoxyphenyl-1-methyl-1-propionoxypiperidine in 100 ml. of benzene during 30 minutes. The mixture was refluxed for 2 hours, washed with water and then 10% HCl, dried with Na2 SO4 and evaporated to dryness to give 23 g. (90%) of oily carbamate; ν1710- 1705, 1250cm -1. From the water and acid washings 2 g. (10%) of 1-m-methoxyphenyl-1-methyl-1-propionoxypiperidine was recovered.
The 23 g. of carbamate and 300 ml. of 23% HCl were refluxed together for 12.5 hr., washed with benzene, made alkaline with sodium hydroxide pellets, and extracted with benzene. Drying and evaporation of the benzene gave 11.6 g. of an oil which was converted to the hydrochloride. Recrystallization from ethyl alcohol gave 11.5 g. (52%) of plates: mp 205°-207°; ν Nujol 1700 cm- 1. Anal. (C15 H22 ClNO2)C,H,Cl,N.
EXAMPLE 3 Preparation of 1-butyl-4-m-hydroxyphenyl-4 -propionylpiperidine hydrobromide
1.6 g. of butyl iodide, 2.0 g. of 4-m-methoxyphenyl-4-propionylpiperidine hydrochloride, 3.0 g. of potassium bicarbonate and 50 ml. of 2-butanone were refluxed (stirring) for 5 hours and evaporated to dryness. The residue was treated with chloroform and water. The chloroform layer was washed with water, dried over sodium sulfate and evaporated to given an oil. The oil and 6 ml. of 48% hydrogen bromide were refluxed for 30 minutes and evaporated to dryness in vacuo. Recrystallization of the residue from ethanol gave in 89% yield 1-butyl-4-m-hydroxyphenyl-4-propionylpiperidine hydrobromide melting point 217°-218°.
EXAMPLE 4 Preparation of 1-amyl-4-m-hydroxyphenyl-4-propionylpiperidine hydrobromide
0.6 g. of amylbromide, 1 g. of 4-m-methoxyphenyl-4-propionylpiperidine hydrochloride, 1.5 g. of potassium bicarbonate and 25 ml. of dimethylformamide were kept at 90° for 6 hours and evaporated to dryness in vacuo; the residue was treated with chloroform and water. Evaporation of the chloroform layer gave 1.1 g. of oil which was demethylated with 5 ml. of 48% hydrobromic acid (30 minute reflux). Distillation to dryness in vacuo and recrystallization of the residue from isopropyl alcohol gave 1.1 g. (83%) of 1-amyl-4-m-hydroxyphenyl-4-propionylpiperidine hydrobromide having a melting point of 189.5°-190°.
EXAMPLE 5 Preparation of 1-hexyl-4-m-hydroxyphenyl-4-propionylpiperidine hydrobromide
As described in the preparation of 1-amyl-4-m-hydroxyphenyl-4-propionyl-hydrobromide (Example 4), the hydrobromide of 1-hexyl-4-m-hydroxyphenyl-4-propionylpiperidine was obtained in 85% yield from hexyl bromide and 4-m-methoxyphenyl-4-propionylpiperidine hydrochloride (15 hours, 80°), and had a melting point of 179°-181°.
EXAMPLE 6 Preparation of 1-heptyl-4-m-hydroxyphenyl-4-propionylpiperidine hydrobromide
1-Heptyl-4-m-hydroxyphenyl-4-propionylpiperidine hydrobromide was obtained in 78% yield, as described for the procedure for obtaining 1-hexyl-4-m-hydroxyphenyl-1-propionylpiperidine hydrobromide, using heptyl bromide; plates, melting point 147°-149°, from acetone.Preparation of TabletsTablet Formulation Per Tablet______________________________________1-Amyl-4-m-hydroxyphenyl-4-propionyl- piperidine hydrobromide 100 mg.Lactose, U.S.P. 202 mg.Corn Starch, U.S.P. 80 mg.Amijel BO11* 20 mg.Calcium Stearate 8 mg.Total Weight 410 mg.______________________________________ *A prehydrolyzed food grade corn starch. Any similar prehydrolyzed corn starch may be used.
PROCEDURE
1-Amyl-4-m-hydroxyphenyl-4-propionyl-piperidine hydrobromide, lactose, corn starch and Amijel BOll are blended in a suitable mixer. The mixture is granulated to a heavy paste with water and the moist mass is passed through a No. 12 screen. It is then dried overnight at 100°F. The dried granules are passed through a No. 16 screen and transferred to a suitable mixer. The calcium stearate is added and mixed until uniform. The mixture is compressed at a tablet weight of 410 mg. using tablet punches having a diameter of approximately 3/8 inch. (Tablets may be either flat or biconvex and may be scored if desired.)
Preparation of Tablets                                                    
Tablet Formulation                                                        
                        Per Tablet                                        
______________________________________                                    
1-Amyl-4-m-hydroxyphenyl-4-propionyl-                                     
 piperidine hydrobromide   25 mg.                                         
Dicalcium Phosphate Dihydrate, Unmilled                                   
                          175 mg.                                         
Corn Starch                24 mg.                                         
Magnesium Stearate         1 mg.                                          
Total Weight              225 mg.                                         
______________________________________
PROCEDURE
1-Amyl-4-m-hydroxyphenyl-4-propionyl-piperidine hydrobromide and corn starch are mixed together and passed though a No. 00 screen in Model "J" Fitzmill with hammers forward. This premix is then mixed with dicalcium phosphate and one-half of the magnesium stearate, passed though a No. 1A screen in Model "J". The slugs are passed through a No. 2A plate in a Model "D" Fitzmill at slow speed with knives forward, and the remaining magnesium stearate is added. The mixture is mixed and compressed.
Preparation of Capsules                                                   
Capsule Formulation                                                       
                        Per Capsule                                       
______________________________________                                    
1-Amyl-4-m-hydroxyphenyl-4-propionyl-                                     
 piperidine hydrobromide   50 mg.                                         
Lactose, U.S.P.           125 mg.                                         
Corn Starch, U.S.P.        30 mg.                                         
Talc, U.S.P.               5 mg.                                          
Total Weight              210 mg.                                         
______________________________________
PROCEDURE
1-Amyl-4-m-hydroxyphenyl-4-propionyl-piperidine hydrobromide is mixed with lactose and corn starch in a suitable mixer. The mixture is further blended by passing through a Fitzpatric Comminuting Machine with a No. 1A screen with knives forward. The blended powder is returned to the mixer, the talc added and blended thoroughly. The mixture is filled into No. 4 hard shell gelatin capsules on a Parke Davis capsulating machine.

Claims (5)

I claim:
1. A compound of the formula ##SPC4##
wherein R is alkyl of 4 to 7 carbon atoms or a pharmaceutically acceptable acid addition salt thereof.
2. The compound in accordance with claim 1, 1-butyl-4-m-hydroxyphenyl-4-propionylpiperidine.
3. The compound in accordance with claim 1, 1-amyl-4-m-hydroxyphenyl-4-propionylpiperidine.
4. The compound in accordance with claim 1, 1-hexyl-4-m-hydroxyphenyl-4-propionylpiperidine.
5. The compound in accordance with claim 1, 1-heptyl-4-m-hydroxyphenyl-4-propionylpiperidine.
US05/478,547 1974-06-11 1974-06-11 1-Alkyl-4-m-hydroxyphenyl-4-propionyl piperidines Expired - Lifetime US3970656A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US05/478,547 US3970656A (en) 1974-06-11 1974-06-11 1-Alkyl-4-m-hydroxyphenyl-4-propionyl piperidines

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US05/478,547 US3970656A (en) 1974-06-11 1974-06-11 1-Alkyl-4-m-hydroxyphenyl-4-propionyl piperidines

Publications (1)

Publication Number Publication Date
US3970656A true US3970656A (en) 1976-07-20

Family

ID=23900371

Family Applications (1)

Application Number Title Priority Date Filing Date
US05/478,547 Expired - Lifetime US3970656A (en) 1974-06-11 1974-06-11 1-Alkyl-4-m-hydroxyphenyl-4-propionyl piperidines

Country Status (1)

Country Link
US (1) US3970656A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0030526A1 (en) * 1979-12-05 1981-06-17 Astra Läkemedel Aktiebolag New phenyl-azacycloalkanes, processes for preparation and pharmaceutical preparations for such compounds
WO2005037269A1 (en) * 2003-10-21 2005-04-28 Dainippon Sumitomo Pharma Co., Ltd. Novel piperidine derivative

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
grumbach et al., J. Pharm. & Exptl. Therap., 149:385-396, (1965). *
Kutter, J. Med. Chem., 13: 801-805, (1970). *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0030526A1 (en) * 1979-12-05 1981-06-17 Astra Läkemedel Aktiebolag New phenyl-azacycloalkanes, processes for preparation and pharmaceutical preparations for such compounds
WO2005037269A1 (en) * 2003-10-21 2005-04-28 Dainippon Sumitomo Pharma Co., Ltd. Novel piperidine derivative
US20070078120A1 (en) * 2003-10-21 2007-04-05 Hitoshi Ban Novel piperidine derivative

Similar Documents

Publication Publication Date Title
US4194045A (en) 1-(3,3-Diaryl-3-oxadiazolalkyl)-4-phenyl-4-piperidinomethanols and related compounds
US4012393A (en) 2-[5-(CYCLIC AMINO) ETHYL-10,11-DIHYDRO-5H-dibenzo[a,d]-cyclohepten-5- yl]-5
CH648553A5 (en) NEW 3,4-DIHYDRO-5H-2,3-BENZODIAZEPINE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF.
US3639477A (en) Novel propoxyguanidine compounds and means of producing the same
US4510156A (en) Bisindolyl alkylene ureas lipid absorption-inhibiting agents and their use thereas
US3996214A (en) 5-(1,1-Diphenyl-4-(cyclic amino) but-2-trans-en-1-yl)-2-alkyl-1,3,4-oxadiazoles and intermediates thereto
US4518712A (en) Piperazine derivative and analgesic composition containing the same
IE44639B1 (en) Oxadiazoloyl-substituted compounds having pharmacological activity
JPS6216942B2 (en)
US3970656A (en) 1-Alkyl-4-m-hydroxyphenyl-4-propionyl piperidines
US4056626A (en) Pharmaceutical composition containing benzofuran derivative
US4113777A (en) 2- OR 4-Hydroxy-3,5-dihalo-benzylamines and salts thereof
US3459767A (en) Aminomethylindoles
US4232158A (en) 10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imines
US3505404A (en) 3,3-dialkyl-1-phenyl-1-indanalkylamines
US2933532A (en) Substituted 1-phenyl-2-hydrazino-propanes
JPH036149B2 (en)
US3590041A (en) Novel halo-substituted cinnamic acid heterocyclic amides
US4006183A (en) Substituted α-methylsulfinyl-o-toluidines
US3726868A (en) Phenyl and substituted phenylsulfonylallyl amines and substituted amines
US3118933A (en) N-(alpha-methyl-2, 4-dichlorophenethyl) hydroxylamine and its salts
US3998965A (en) 4-Aminoalkyl-4-cyano-4-phenyl-butanoic acid esters
US4028364A (en) 2-Azabicyclo[2.2.2.]octan-2-yl-diphenyl-alkanones and related compounds
US3281468A (en) beta-phenyl-beta-hydroxyethylamines
JPS6410512B2 (en)